Detalles de la búsqueda
1.
Prognostic factors and adjuvant systemic therapy for patients with HER2-positive T1N0 breast cancer: evidence from a real-world study with long-term follow-up.
Breast Cancer Res Treat
; 197(3): 569-582, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36469156
2.
Combined analysis of receptor expression reflects inter-and intra-tumor heterogeneity in HR+/HER2+ breast cancer.
Breast Cancer Res Treat
; 194(2): 221-230, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35699854
3.
Prognostic factors and benefit populations of ovarian function suppression in premenopausal HR+/HER2+ early-stage breast cancer patients who received trastuzumab: Evidence from a real-world study with long-term follow-up.
Thorac Cancer
; 15(6): 439-447, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38185807
4.
Differences in clinical characteristics and prognosis between breast neuroendocrine carcinoma and breast invasive ductal carcinoma: A multicentre population-based study from China.
Cancer Med
; 12(8): 9644-9649, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36952359
5.
The Effects of Endocrine Therapies on Lipid Profiles in Chinese Young Women With Early Breast Cancer.
Front Oncol
; 11: 759595, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34926260
6.
Management of breast cancer brain metastases: Focus on human epidermal growth factor receptor 2-positive breast cancer.
Chronic Dis Transl Med
; 3(1): 21-32, 2017 Mar 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-29063053
Resultados
1 -
6
de 6
1
Próxima >
>>